Finally, perhaps the most striking finding from these studies is that low levels of activated FGFR1 have rapid and potent effects on cardiac contractility without any pathological effects, suggesting that targeted activation of the FGF signaling pathway may be beneficial to patients with heart failure and poor systolic function. This evidence concerns the gene FGFR1 and heart failure.